A New Clinical Framework for Managing NMDA Antagonist Tolerability
A 2026 analysis published in Psychiatric Times takes a closer look at something practitioners and patients rarely see laid out plainly: how often people stop NMDA receptor antagonist therapy—ketamine infusions and intranasal esketamine (Spravato)—and exactly what drives those decisions. The article's central argument is practical and pointed: clinicians are moving too slowly when it comes to dose optimization and treatment switching, and that hesitation is costing patients time on the path to remission.
For anyone using or considering low-dose ketamine for depression, the findings carry meaningful implications. Understanding the side effect landscape—and knowing when tolerability data should trigger a clinical conversation—matters as much as understanding whether the treatment is working in the first place.
What the Side Effect Data Actually Shows
NMDA receptor antagonists produce a distinctive side effect signature that sets them apart from conventional antidepressants. The most commonly reported effects—dissociation, perceptual distortion, dizziness, nausea, and transient blood pressure elevation—are typically acute, meaning they appear during or shortly after administration and resolve within hours. This time-limited nature is one reason ketamine's tolerability profile is often described as manageable, but the Psychiatric Times review highlights that 'manageable' doesn't mean universally tolerable or without clinical consequence.
Discontinuation rates across the NMDA antagonist class vary considerably depending on the formulation, dose, setting, and patient population studied. Intranasal esketamine trials have documented discontinuation rates in the range of 10–20% due to adverse events, while IV ketamine real-world data tends to show lower dropout from side effects—though this partly reflects differences in patient selection and monitoring intensity. The key nuance the article surfaces is that discontinuation reasons are often mixed: patients who stop aren't always stopping because of intolerable side effects alone. Lack of sufficient efficacy and logistical burden (frequency of visits, cost, scheduling) are also major drivers, and these factors interact in ways that aggregate dropout statistics can obscure.
For low-dose protocols specifically, the tolerability picture tends to be more favorable than what higher-dose or anesthetic-range regimens produce. Lower doses generally reduce the intensity of dissociation and hemodynamic effects, which is one clinical rationale for exploring sub-anesthetic ranges in depression care. That said, 'lower dose' is not a synonym for 'no side effects,' and individual variability in response remains substantial.
The Optimization Argument: Move Faster, Track Better
The most actionable thread in the Psychiatric Times piece is its critique of clinical inertia. The authors argue that too many practitioners maintain a static dose or administration schedule even when early response data—PHQ-9 scores, patient-reported side effect burden, functional metrics—suggest the current approach isn't working. The recommendation is explicit: use structured outcome tracking from the first session, and treat the absence of meaningful improvement by weeks four to six as a decision point rather than a reason to wait longer.
This framing has direct relevance for how patients should think about their own treatment. A course of ketamine that produces significant dissociation without corresponding mood improvement is not a treatment that should simply be continued indefinitely in the hope that tolerance to side effects will eventually yield benefit. The data suggest that earlier pivoting—whether to dose adjustment, alternative formulation, or a different treatment altogether—produces better long-term outcomes than prolonged exposure to a suboptimal regimen.
The article also emphasizes the role of systematic side effect tracking, not just efficacy tracking. PHQ-9 is the most widely cited tool for depression symptom monitoring, but pairing it with a consistent side effect log (dissociation severity, nausea, blood pressure readings, next-day cognitive fog) gives clinicians the data they need to make informed adjustments rather than relying on patient recall during a brief appointment.
Key Takeaway for Low-Dose Ketamine Patients
If you're experiencing notable side effects without clear mood benefit after several sessions, that pattern is clinically significant—not something to simply endure. Bring structured notes to your next appointment: rate your dissociation, nausea, and next-day functioning after each session, and track your PHQ-9 over time. This data gives your provider what they need to adjust your dose sooner rather than later. Waiting passively for tolerability to improve on its own is not supported by the current evidence.
What This Means for Monitoring and Long-Term Expectations
One important caveat worth naming: much of the discontinuation and tolerability data cited in reviews like this one comes from clinical trials of esketamine or higher-dose IV ketamine protocols. Low-dose oral, sublingual, and lower-concentration IV regimens have a smaller but growing evidence base, and their tolerability profiles don't map perfectly onto trial data from different formulations. That's not a reason to dismiss the findings—the underlying pharmacology and side effect mechanisms are shared—but it's a reason to interpret aggregate statistics with some care rather than assuming they apply uniformly to every protocol.
What does translate well across formulations is the general principle: systematic tracking beats intuition. Whether you're on a structured infusion schedule or a maintenance oral protocol, knowing your symptom trajectory and your side effect burden over time puts you in a much stronger position to have productive clinical conversations. The evidence increasingly supports treating ketamine as a dynamic, adjustable intervention rather than a fixed prescription to either tolerate or abandon.
As the field matures and more real-world data accumulates on diverse ketamine modalities, expect the guidance on optimal dosing windows, maintenance intervals, and side effect thresholds to become more refined. For now, the clearest takeaway from this 2026 analysis is that both patients and clinicians benefit from moving away from a passive 'wait and see' stance toward active, data-informed decision-making at every stage of treatment.
Share